Full-Time

Data and analytics

SAP Planning expert, Sac','Tm1

Posted on 11/23/2025

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Madrid, Spain

In Person

Category
Data & Analytics (2)
,
Required Skills
Python
JavaScript
SQL
REST APIs
VBA
Data Analysis
HTML/CSS
Requirements
  • Bachelor's degree in Computer Science, Information Technology, Business, or related field.
  • Understanding of Agile methodologies and experience with Agile tools.
  • Excellent communication, collaboration, and interpersonal skills.
  • Ability to balance customer-centric thinking with technical feasibility and stakeholder needs.
  • Strong analytical and problem-solving skills.
  • Proficiency in English.
  • Extensive, proven experience (minimum 5 years) as a Planning Analytics/TM1 Architect and Developer.
Responsibilities
  • Extensive, proven experience (min. 5 years) as a Planning Analytics/TM1 Architect and Developer: Proficiency in setting up cubes, dimensions.
  • Extensive, proven experience (min. 5 years) as a Planning Analytics/TM1 Architect and Developer: Capable of writing complex, dependent Turbo Integrator processes (TIs).
  • Extensive, proven experience (min. 5 years) as a Planning Analytics/TM1 Architect and Developer: Capable of writing complex Rules knowing the rule-engine of TM1.
  • Extensive, proven experience (min. 5 years) as a Planning Analytics/TM1 Architect and Developer: Building PAW (Planning Analytics Workspace) workbooks.
  • Extensive, proven experience (min. 5 years) as a Planning Analytics/TM1 Architect and Developer: Understanding REST API of TM1, being able to write API calls with complex and parameter driven MDX queries.
  • Extensive, proven experience (min. 5 years) as a Planning Analytics/TM1 Architect and Developer: Indepth know-how of TM1 security model and being able to implement complex security set-up within Planning Analytics/TM1.
  • Extensive, proven experience (min. 5 years) as a Planning Analytics/TM1 Architect and Developer: Expert user of Perspectives and PAFE Excel Add-ins.
  • Extensive, proven experience (min. 5 years) with programming languages at minimum with the following: VBA.
  • Extensive, proven experience (min. 5 years) with programming languages at minimum with the following: Python.
  • Extensive, proven experience (min. 5 years) with programming languages at minimum with the following: Java Script / CSS.
  • Extensive, proven experience (min. 5 years) with relational database systems and primary knowledge with: SQL language.
  • Extensive, proven experience (min. 5 years) with relational database systems and primary knowledge with: MDX query language.
  • Expertise in designing, implementing, and testing financial planning applications.
  • Serving as a Business Analyst by collaborating closely with customers to understand their processes and requirements.
  • Documenting user requirements and creating Functional Specification and Design documents.
  • Demonstrated ability to self-organize and take proactive measures.
  • Roche-specific: Proficiency in English.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • PathAI can strengthen AI pathology workflows and biomarker discovery.
  • Elecsys pTau217 expands Roche's Alzheimer diagnostics beyond specialist laboratory settings.
  • Nurix collaboration deepens Roche's reach into protein degradation and hematology.

What critics are saying

  • Swiss franc strength keeps distorting reported growth and investor perception.
  • Patent expirations on older medicines force rapid replacement from newer assets.
  • CT-388 must beat Novo Nordisk and Eli Lilly to matter.

What makes Roche unique

  • Roche combines pharmaceuticals, diagnostics, and digital pathology across one healthcare platform.
  • Founded in Basel in 1896, Roche built scale through branded medicines.
  • Genentech integration made Roche the world's largest biotechnology company.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Roche who can refer or advise you

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE